OakChart

Scribe Therapeutics Inc

SCTXHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

16.86-0.50 (-2.88%)
2026-11-12 03:20 CET
Market cap
319.19 USD m
Revenue, TTM
1.92 USD m
Net income, TTM
-6.48 USD m
Free cash flow, TTM
-5.35 USD m
EPS diluted, TTM
-0.34
P/E
-
Compare

Price

SCTX against its 20 and 50-day averages
2050miss
20.0030.0040.001.1M2.2MVolumeJul 26Aug 26Sep 26Oct 26Nov 26SCTXclose 16.8620-day 17.2650-day 21.6916.8652w high52w low

57.4% under the 52-week high of 39.60 on 20 Aug 2026. 52-week low 13.50 on 5 Oct 2026. Last 15 sessions, 33.7% high to low

Volume 0.96× normal · the line is the 50-bar volume average

Profile

SCTX
52-week range, 13% of the way up
13.5039.60

Scribe Therapeutics, Inc. is a clinical-stage biotechnology company. It is engaged in the development of in vivo therapies. It develops custom engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company was founded in June 2017 by Jennifer A. Doudna, Benjamin L. Oakes, David F. Savage, and Brett T. Staahl and is headquartered in Alameda, CA.

IndexRUT
Employees98
IPOJul 24, 2026
ATR, 14d2.10
Rel volume0.96
Short float13.83%
Insider own36.14%
Inst own28.45%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap319.18M
Enterprise Value439.80M
Income-
Sales-
Book/sh-8.71
Cash/sh2.27
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees98
IPOJul 24, 2026

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B-
P/C7.42
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio0.57
Current Ratio0.57
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / Yes

Earnings

EPS (ttm)-
EPS next Y-
EPS next Q-0.85
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y- -
Sales past 3/5Y- -
EPS Y/Y TTM-
Sales Y/Y TTM-
EPS Q/Q-
Sales Q/Q-
EarningsSep 02 AMC
EPS/Sales Surpr.27.58% -38.16%

Ownership

Insider Own36.14%
Insider Trans224.01%
Inst Own28.45%
Inst Trans35.41%
ROA-
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-2.32%
SMA50-22.28%
SMA200-26.76%
Trades-

Technical

Shs Outstand18.93M
Shs Float12.09M
Short Float13.83%
Short Ratio4.33
Short Interest1.67M
52W High39.60 -57.42%
52W Low13.50 24.89%
Volatility10.66% 11.63%
ATR (14)2.10
RSI (14)44.82
Beta-
Rel Volume0.96
Avg Volume385.67K
Volume369,735

Performance

Perf Week0.48%
Perf Month-11.82%
Perf Quarter-17.23%
Perf Half Y-
Perf YTD-32.56%
Perf Year-
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price57.00
Prev Close17.36
Price16.86
Change %-2.88%

Analyst ratings

latest 4 of 4
DateActionAnalystRating changeTargetImplied
Aug 31, 2026InitiatedHH.C. WainwrightBuy$60+255.9%
Aug 18, 2026InitiatedWWells FargoOverweight$60+255.9%
Aug 18, 2026InitiatedLLeerink PartnersOutperform$37+119.5%
Aug 18, 2026InitiatedGGuggenheimBuy$50+196.6%

Peers

Mkt cap
TickerCompanyMkt cap
CRSPCRISPR Therapeutics AG4.44B
PRMEPrime Medicine Inc779.92M
BEAMBeam Therapeutics Inc2.67B
NTLAIntellia Therapeutics Inc1.60B
EDITEditas Medicine Inc367.33M
DTILPrecision Biosciences Inc255.61M
SLNSilence Therapeutics Plc ADR1.23B
ARWRArrowhead Pharmaceuticals Inc6.97B
MGXMetagenomi Therapeutics Inc28.57M
IONSIonis Pharmaceuticals Inc4.72B

Insider trading

7 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
AH Bio Fund II, L.P.10% OwnerJul 27 '26Buy15.00333,3334,999,9952,385,075Jul 29 07:09 PM
GORDON CARL LDirectorJul 27 '26Buy15.001,000,00015,000,0001,348,825Jul 29 06:50 PM
ORBIMED ADVISORS LLCDirectorJul 27 '26Buy15.001,000,00015,000,0001,348,825Jul 29 06:47 PM
Aghazadeh BehzadDirectorJul 24 '26Buy15.152,383,33336,115,4953,080,983Jul 28 09:30 PM
Aghazadeh BehzadDirectorJul 28 '26Buy18.257,905144,2663,088,888Jul 28 09:30 PM
Lucas SvetlanaChief Business OfficerJul 23 '26Buy15.003,00045,0003,000Jul 27 09:42 PM
Parrot DavidChief Financial OfficerJul 23 '26Buy15.002,66639,9901,333Jul 27 09:20 PM

Held by

AUM
TickerCompanyAUM
ARKGARK Genomic Revolution ETFAUM: 1.97B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
IWCiShares Micro-Cap ETFAUM: 1.22B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-09-02-2.620-3.618-2.6201.923.115
2026Q12026-06-03-4.720--0.9872.17--
2026Q3---0.854--3.725
2026Q4---0.843--3.715
2027Q1---0.664--2.653
2027Q2---0.672--2.252
2027Q3---0.815--1.902
2027Q4---0.885--1.602

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
No annual earnings.

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-09-035103.720.0011.00
2026Q3S2026-09-025003.110.007.95
2026Q3S2026-08-285003.110.007.95
2026Q3S2026-08-174003.110.007.95
2026Q3R2026-09-03210-1.11-1.46-0.76
2026Q3R2026-09-02200-1.21-1.46-0.95
2026Q3R2026-08-17200-1.21-1.46-0.95
2026Q3E2026-10-27530-0.85-1.46-0.42
2026Q3E2026-09-03530-0.85-1.46-0.42
2026Q3E2026-09-02500-1.03-1.46-0.82
2026Q3E2026-08-28500-1.03-1.46-0.82
2026Q3E2026-08-17400-1.03-1.46-0.82
2026Q2S2026-08-285003.110.007.95
2026Q2S2026-08-174003.110.007.95

Estimate history

EPS, annual-2.719-1.241
Period20242025
EPS, quarterly-0.195-0.523-0.987-0.342
PeriodQ1 '25Q2 '25Q1 '26Q2 '26
Sales, annual27.41351.174
Period20242025
Sales, quarterly17.1254.8982.2331.918
PeriodQ1 '25Q2 '25Q1 '26Q2 '26
Shares, annual17.57717.57718.932
Period20242025MRQ
Shares, quarterly17.57718.93217.57718.932
PeriodQ1 '25Q2 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY
Total Revenue1.9251.1727.41
Cost of Goods Sold Incl. D&A0.793.083.28
Gross Profit1.1348.1024.13
Selling, General and Administrative Excl. Other10.5370.5966.96
Research and Development8.1857.7254.19
Other Operating Expense0.000.000.00
Operating Income-9.39-22.49-42.83
Interest Expense0.282.392.38
Unusual Expense-3.022.05-1.50
Net Income Before Taxes-6.26-23.61-37.56
Income Taxes0.21-1.8010.22
Consolidated Net Income-6.48-21.81-47.79
Net Income From Continuing Operations-6.48-21.81-47.79
Net Income-6.48-21.81-47.79
EPS (Recurring)-0.45-1.16-2.78
EPS (Basic, Before Extraordinaries)-0.34-1.24-2.72
EPS (Diluted)-0.34-1.24-2.72
EBITDA-8.61-19.41-39.55
Non-Operating Income (Expense)0.383.336.15
Other After Tax Adjustments0.000.000.00
Stock Option Compensation Expense0.183.272.25
Gross Margin-93.9988.02
Operating Margin--43.95-156.24
Net Margin--42.62-174.32
Shares Outstanding18.9317.5817.58
Market Capitalization319.19319.19-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q22025Q1
Total Revenue1.922.234.9017.12
Cost of Goods Sold Incl. D&A0.790.770.840.86
Gross Profit1.131.464.0616.26
Selling, General and Administrative Excl. Other10.5313.8915.6921.82
Research and Development8.1810.6713.1715.24
Other Operating Expense0.000.000.000.00
Operating Income-9.39-12.43-11.63-5.56
Interest Expense0.280.600.600.60
Unusual Expense-3.024.61-0.73-1.35
Net Income Before Taxes-6.26-17.12-10.62-3.74
Income Taxes0.210.23-0.71-0.32
Consolidated Net Income-6.48-17.35-9.90-3.42
Net Income From Continuing Operations-6.48-17.35-9.90-3.42
Net Income-6.48-17.35-9.90-3.42
EPS (Recurring)-0.45-0.80-0.55-0.25
EPS (Basic, Before Extraordinaries)-0.34-0.99-0.52-0.19
EPS (Diluted)-0.34-0.99-0.52-0.19
EBITDA-8.61-11.65-10.79-4.70
Non-Operating Income (Expense)0.380.520.881.06
Other After Tax Adjustments0.000.000.000.00
Stock Option Compensation Expense0.181.560.530.53
Gross Margin59.0765.3882.9394.97
Operating Margin-489.83-556.52-237.38-32.45
Net Margin-337.70-776.85-202.18-20.00
Shares Outstanding18.9317.5818.9317.58
Market Capitalization319.19---

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY
Cash & Short Term Investments57.96105.17
Short Term Receivables7.353.52
Inventories0.000.00
Other Current Assets1.621.69
Total Current Assets66.93110.37
Net Property, Plant & Equipment10.0713.18
Total Investments and Advances0.680.68
Deferred Tax Assets2.183.04
Other Assets0.543.75
Total Assets80.40131.01
Short Term Debt Incl. Current Port. of LT Debt36.621.12
Accounts Payable4.573.79
Other Current Liabilities27.8730.11
Total Current Liabilities69.0635.02
Long Term Debt4.8040.56
Provision for Risks Charges0.000.00
Deferred Tax Liabilities2.183.04
Other Liabilities27.4257.89
Total Liabilities103.46136.51
Non-Equity Reserves0.000.00
Preferred Stock - Carrying Value120.36120.36
Common Equity-143.42-125.86
Total Shareholders Equity-23.06-5.50
Accumulated Minority Interest0.000.00
Total Equity-23.06-5.50
Total Liabilities & Stockholders Equity80.40131.01
Book Value Per Share-8.16-7.16
Tangible Book Value Per Share-8.16-7.16
Full-Time Employees98-
Price to Book Ratio-1.94-
Return on Assets-20.63-
Return on Invested Capital--136.31
Quick Ratio0.973.15
Current Ratio0.973.15

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY
Net Income-6.48-21.81-47.79
Depreciation0.793.083.28
Other Funds (Non Cash)1.319.914.49
Funds from Operations-4.38-8.82-40.02
Extraordinary Item0.000.000.00
Changes in Working Capital-0.95-36.39-5.22
Cash from Operating Activities-5.34-45.21-45.23
Capital Expenditures-0.01-1.27-1.35
Net Assets From Acquisitions0.000.000.00
Sale of Fixed Assets and Businesses0.000.000.00
Purchase or Sale of Investments21.9346.5414.36
Purchase of Investments0.00-58.17-124.05
Sale Or Maturity of Investments21.93104.70138.41
Other Uses0.000.000.00
Other Sources0.000.000.00
Cash from Investing Activities21.9245.2713.01
Cash Dividends Paid0.000.000.00
Change in Capital Stock-1.380.14-0.22
Repurchase of Common Pref Stock0.000.000.00
Sale of Common Pref Stock-1.380.14-0.22
Proceedsfrom Stock Options-1.520.00-0.69
Issuance or Reduction of Debt, Net0.000.000.00
Change in Long Term Debt0.000.000.00
Issuance of Long Term Debt0.000.000.00
Reduction of Long Term Debt0.000.000.00
Net Financing Active Other Cash Flow0.000.000.00
Other Financing Activities Uses0.000.000.00
Cash from Financing Activities-1.380.14-0.22
Net Change in Cash15.210.19-32.44
Free Cash Flow-5.35-46.48-46.58
Deferred Taxes & Investment Tax Credit-0.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q22025Q1
Cash & Short Term Investments43.0149.73--
Short Term Receivables1.231.52--
Inventories0.000.00--
Other Current Assets0.861.15--
Total Current Assets45.1052.40--
Net Property, Plant & Equipment8.549.32--
Total Investments and Advances0.680.68--
Other Assets3.612.82--
Total Assets57.9365.21--
Short Term Debt Incl. Current Port. of LT Debt39.1741.87--
Accounts Payable2.775.12--
Other Current Liabilities36.7632.73--
Total Current Liabilities78.7079.72--
Long Term Debt4.104.46--
Provision for Risks Charges0.000.00--
Other Liabilities19.6219.41--
Total Liabilities102.42103.59--
Non-Equity Reserves0.000.00--
Preferred Stock - Carrying Value120.36120.36--
Common Equity-164.85-158.74--
Total Shareholders Equity-44.49-38.38--
Accumulated Minority Interest0.000.00--
Total Equity-44.49-38.38--
Total Liabilities & Stockholders Equity57.9365.21--
Book Value Per Share-8.71-9.03--
Tangible Book Value Per Share-8.71-9.03--
Full-Time Employees8289--
Price to Book Ratio-1.94---
Quick Ratio0.570.66--
Current Ratio0.570.66--

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q22025Q1
Net Income-6.48-17.35-9.90-3.42
Depreciation0.790.770.840.86
Other Funds (Non Cash)1.317.390.863.66
Funds from Operations-4.38-9.18-8.211.10
Extraordinary Item0.000.000.000.00
Changes in Working Capital-0.951.621.57-14.72
Cash from Operating Activities-5.34-7.55-6.63-13.62
Capital Expenditures-0.01-0.02-0.44-0.49
Net Assets From Acquisitions0.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.00
Purchase or Sale of Investments21.9315.573.1021.41
Purchase of Investments0.00-4.84-21.62-10.10
Sale Or Maturity of Investments21.9320.4124.7231.51
Other Uses0.000.000.000.00
Other Sources0.000.000.000.00
Cash from Investing Activities21.9215.552.6620.92
Cash Dividends Paid0.000.000.000.00
Preferred Dividends (Cash Flow)--0.000.00
Change in Capital Stock-1.38-0.410.05-0.00
Repurchase of Common Pref Stock0.000.000.000.00
Sale of Common Pref Stock-1.38-0.410.05-0.00
Proceedsfrom Stock Options-1.52-0.500.00-0.00
Issuance or Reduction of Debt, Net0.000.000.000.00
Change in Long Term Debt0.000.000.000.00
Issuance of Long Term Debt0.000.000.000.00
Reduction of Long Term Debt0.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.00
Other Financing Activities Uses0.000.000.000.00
Cash from Financing Activities-1.38-0.410.05-0.00
Net Change in Cash15.217.58-3.927.29
Free Cash Flow-5.35-7.57-7.07-14.11

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3013.83%1.7M12.1M370.05K
2026-10-159.25%1.1M12.1M368.35K
2026-09-3020.40%2.5M12.1M342.80K
2026-09-156.54%0.8M12.1M237.70K
2026-08-316.44%0.8M12.1M261.12K
2026-08-142.61%0.3M10.9M234.92K
2026-07-312.55%0.3M10.3M402.18K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-09-0210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-09-028-KCurrent report2026-09-02SEC
2026-08-03SCHEDULE 13GSEC
2026-07-30SCHEDULE 13DSEC
2026-07-30SCHEDULE 13DSEC
2026-07-294Statement of changes in beneficial ownership of securities2026-07-27SEC
2026-07-294Statement of changes in beneficial ownership of securities2026-07-27SEC
2026-07-294Statement of changes in beneficial ownership of securities2026-07-23SEC
2026-07-294Statement of changes in beneficial ownership of securities2026-07-27SEC
2026-07-29SCHEDULE 13DSEC
2026-07-284Statement of changes in beneficial ownership of securities2026-03-13SEC
2026-07-284Statement of changes in beneficial ownership of securities2026-07-24SEC
2026-07-274Statement of changes in beneficial ownership of securities2026-07-23SEC
2026-07-274Statement of changes in beneficial ownership of securities2026-03-13SEC
2026-07-274Statement of changes in beneficial ownership of securities2026-03-13SEC
2026-07-274Statement of changes in beneficial ownership of securities2026-07-23SEC
2026-07-274Statement of changes in beneficial ownership of securities2026-03-13SEC
2026-07-274Statement of changes in beneficial ownership of securities2026-07-23SEC
2026-07-278-KCurrent report2026-07-27SEC
2026-07-27S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-07-27424B4SEC
2026-07-274Statement of changes in beneficial ownership of securities2026-07-23SEC
2026-07-24FWPFiling under Securities Act Rule 163/433 of free writing prospectuses.SEC
2026-07-23EFFECTEffectiveness filing by commission orderSEC
2026-07-233Initial statement of beneficial ownership of securities2026-07-23SEC
2026-07-233Initial statement of beneficial ownership of securities2026-07-23SEC
2026-07-233Initial statement of beneficial ownership of securities2026-07-23SEC
2026-07-233Initial statement of beneficial ownership of securities2026-07-23SEC
2026-07-233Initial statement of beneficial ownership of securities2026-07-23SEC
2026-07-233Initial statement of beneficial ownership of securities2026-07-23SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-0771.34M700
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Sanofi2.64%
GEODE CAPITAL MANAGEMENT, LLC1.30%
Menlo Ventures Management, L.P.0.52%
Sumitomo Mitsui Trust Group, Inc.0.40%
UBS Group AG0.38%
Nuveen, LLC0.22%
Bank of New York Mellon Corp0.11%
RHUMBLINE ADVISERS0.05%
DEUTSCHE BANK AG\0.04%
CITIGROUP INC0.03%

Funds

Fund% owned
ARK Genomic Revolution ETF2.18%
Franklin Biotechnology Discovery Fund0.84%
Fidelity Nasdaq Composite Index Fund0.10%
Tema Healthcare AI ETF0.01%
VANGUARD RUSSELL 2000 INDEX FUND0.00%
BlackRock Advantage Small Cap Core Fund0.00%
Strategic Advisers U.S. Total Stock Fund0.00%

OakChart. SCTX. Cached 15 minutes.

Some panels did not load: news.